OPTIMISATION of the prostate-specific antigen (PSA) test has been earmarked through the utilisation of methods from personalised medicine…

Seattle, February 26, 2015 – Gilead Sciences, Inc. (NASDAQ: GILD) today announced results from a Phase 3 study, ION-4, evaluating the once-daily…

Seattle, February 26, 2015 – Gilead Sciences, Inc. (NASDAQ: GILD) today announced detailed 48week results from two Phase 3 studies (Studies 104 and 111)…

Lugano, 25 February 2015 – Within the “umbrella” of rare diseases, rare cancer patients confront particular problems. Most rare diseases have an…

DEVELOPMENT of treatments for leukaemia and lymphoma could be aided by a new computer model that simulates the development of blood cells…

BREAST cancer patients with small node-negative HER2-positive tumours achieved 3-year survival approaching 100% with adjuvant paclitaxel and trastuzumab…

PROGRAMMABLE biomaterial that is capable of spontaneously assembling into a fighting structure once injected into a living body has the potential to…

Data have been presented on the use of Hospira’s Inflectra (infliximab) at the European Crohn’s and Colitis Organisation Inflammatory Bowel Diseases (ECCO-ibd) conference.